Everest Medicines Partners with Corxel to Introduce CARDAMYST™ Nasal Spray in Greater China

Everest Medicines has signed a key agreement with Corxel to launch the innovative CARDAMYST™ nasal spray across Greater China. This venture marks a significant move that aims to revolutionize treatment accessibility for patients in the region. Through the acquisition of CARDAMYST’s rights, Everest Medicines embarks on a path toward enhancing cardiovascular care delivery. The agreement entails an initial payment of US$30 million to Corxel, with potential milestone payments reaching up to US$20 million. With strong strategic foundations, this collaboration positions Everest Medicines as a frontrunner in advancing cardiovascular therapies. The nascent partnership underscores a commitment to addressing critical healthcare gaps,…